KR20240023373A - Manufacturing method of fermented coffee bean enhancing of biologically active substance and fermented coffee bean manufactured same - Google Patents
Manufacturing method of fermented coffee bean enhancing of biologically active substance and fermented coffee bean manufactured same Download PDFInfo
- Publication number
- KR20240023373A KR20240023373A KR1020230104699A KR20230104699A KR20240023373A KR 20240023373 A KR20240023373 A KR 20240023373A KR 1020230104699 A KR1020230104699 A KR 1020230104699A KR 20230104699 A KR20230104699 A KR 20230104699A KR 20240023373 A KR20240023373 A KR 20240023373A
- Authority
- KR
- South Korea
- Prior art keywords
- coffee beans
- fermented coffee
- fermented
- content
- acid
- Prior art date
Links
- 241000533293 Sesbania emerus Species 0.000 title claims abstract description 77
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 19
- 230000002708 enhancing effect Effects 0.000 title description 2
- 229940088623 biologically active substance Drugs 0.000 title 1
- 239000000126 substance Substances 0.000 claims abstract description 28
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 claims abstract description 24
- 230000000975 bioactive effect Effects 0.000 claims abstract description 22
- 238000000034 method Methods 0.000 claims abstract description 21
- WWNNZCOKKKDOPX-UHFFFAOYSA-N N-methylnicotinate Chemical compound C[N+]1=CC=CC(C([O-])=O)=C1 WWNNZCOKKKDOPX-UHFFFAOYSA-N 0.000 claims abstract description 20
- QAIPRVGONGVQAS-DUXPYHPUSA-N trans-caffeic acid Chemical compound OC(=O)\C=C\C1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-DUXPYHPUSA-N 0.000 claims abstract description 20
- 230000001965 increasing effect Effects 0.000 claims abstract description 18
- ZMJBYMUCKBYSCP-UHFFFAOYSA-N Hydroxycitric acid Chemical compound OC(=O)C(O)C(O)(C(O)=O)CC(O)=O ZMJBYMUCKBYSCP-UHFFFAOYSA-N 0.000 claims abstract description 13
- 229940089491 hydroxycitric acid Drugs 0.000 claims abstract description 13
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 claims abstract description 12
- 229960001948 caffeine Drugs 0.000 claims abstract description 12
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 claims abstract description 12
- CWVRJTMFETXNAD-FWCWNIRPSA-N 3-O-Caffeoylquinic acid Natural products O[C@H]1[C@@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-FWCWNIRPSA-N 0.000 claims abstract description 11
- PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 claims abstract description 11
- CWVRJTMFETXNAD-KLZCAUPSSA-N Neochlorogenin-saeure Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-KLZCAUPSSA-N 0.000 claims abstract description 11
- CWVRJTMFETXNAD-JUHZACGLSA-N chlorogenic acid Chemical compound O[C@@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-JUHZACGLSA-N 0.000 claims abstract description 11
- 229940074393 chlorogenic acid Drugs 0.000 claims abstract description 11
- 235000001368 chlorogenic acid Nutrition 0.000 claims abstract description 11
- FFQSDFBBSXGVKF-KHSQJDLVSA-N chlorogenic acid Natural products O[C@@H]1C[C@](O)(C[C@@H](CC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O FFQSDFBBSXGVKF-KHSQJDLVSA-N 0.000 claims abstract description 11
- BMRSEYFENKXDIS-KLZCAUPSSA-N cis-3-O-p-coumaroylquinic acid Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)cc2)[C@@H]1O)C(=O)O BMRSEYFENKXDIS-KLZCAUPSSA-N 0.000 claims abstract description 11
- ACEAELOMUCBPJP-UHFFFAOYSA-N (E)-3,4,5-trihydroxycinnamic acid Natural products OC(=O)C=CC1=CC(O)=C(O)C(O)=C1 ACEAELOMUCBPJP-UHFFFAOYSA-N 0.000 claims abstract description 10
- 235000004883 caffeic acid Nutrition 0.000 claims abstract description 10
- 229940074360 caffeic acid Drugs 0.000 claims abstract description 10
- QAIPRVGONGVQAS-UHFFFAOYSA-N cis-caffeic acid Natural products OC(=O)C=CC1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-UHFFFAOYSA-N 0.000 claims abstract description 10
- 241000233866 Fungi Species 0.000 claims description 17
- 244000113306 Monascus purpureus Species 0.000 claims description 9
- 235000002322 Monascus purpureus Nutrition 0.000 claims description 9
- 229940057059 monascus purpureus Drugs 0.000 claims description 9
- 244000205939 Rhizopus oligosporus Species 0.000 claims description 7
- 235000000471 Rhizopus oligosporus Nutrition 0.000 claims description 7
- 241000228347 Monascus <ascomycete fungus> Species 0.000 claims description 6
- 241000235527 Rhizopus Species 0.000 claims description 6
- 241000228212 Aspergillus Species 0.000 claims description 2
- 239000013543 active substance Substances 0.000 claims 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 abstract description 17
- 230000002401 inhibitory effect Effects 0.000 abstract description 11
- 102100024295 Maltase-glucoamylase Human genes 0.000 abstract description 10
- 108010028144 alpha-Glucosidases Proteins 0.000 abstract description 10
- 229930003935 flavonoid Natural products 0.000 abstract description 8
- 150000002215 flavonoids Chemical class 0.000 abstract description 8
- 235000017173 flavonoids Nutrition 0.000 abstract description 8
- 230000003078 antioxidant effect Effects 0.000 abstract description 6
- 239000000463 material Substances 0.000 abstract description 5
- 240000007154 Coffea arabica Species 0.000 description 34
- 238000000855 fermentation Methods 0.000 description 12
- 230000004151 fermentation Effects 0.000 description 12
- 239000006228 supernatant Substances 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- 238000002835 absorbance Methods 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 230000000052 comparative effect Effects 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 5
- 238000004128 high performance liquid chromatography Methods 0.000 description 5
- 235000007460 Coffea arabica Nutrition 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- ZSLZBFCDCINBPY-ZSJPKINUSA-N acetyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 ZSLZBFCDCINBPY-ZSJPKINUSA-N 0.000 description 4
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 4
- 230000003178 anti-diabetic effect Effects 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 3
- 240000005384 Rhizopus oryzae Species 0.000 description 3
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 235000019634 flavors Nutrition 0.000 description 3
- 238000002376 fluorescence recovery after photobleaching Methods 0.000 description 3
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 3
- 229960001285 quercetin Drugs 0.000 description 3
- 235000005875 quercetin Nutrition 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000010421 standard material Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 102000004146 ATP citrate synthases Human genes 0.000 description 2
- 108090000662 ATP citrate synthases Proteins 0.000 description 2
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 230000002292 Radical scavenging effect Effects 0.000 description 2
- 235000013752 Rhizopus oryzae Nutrition 0.000 description 2
- 241000235546 Rhizopus stolonifer Species 0.000 description 2
- 241001107098 Rubiaceae Species 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 229960005305 adenosine Drugs 0.000 description 2
- 229930013930 alkaloid Natural products 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 235000019658 bitter taste Nutrition 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- MGJZITXUQXWAKY-UHFFFAOYSA-N diphenyl-(2,4,6-trinitrophenyl)iminoazanium Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1N=[N+](C=1C=CC=CC=1)C1=CC=CC=C1 MGJZITXUQXWAKY-UHFFFAOYSA-N 0.000 description 2
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 description 2
- 244000013123 dwarf bean Species 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 2
- 235000021331 green beans Nutrition 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 229960003512 nicotinic acid Drugs 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 238000004445 quantitative analysis Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000003643 water by type Substances 0.000 description 2
- AAWZDTNXLSGCEK-LNVDRNJUSA-N (3r,5r)-1,3,4,5-tetrahydroxycyclohexane-1-carboxylic acid Chemical compound O[C@@H]1CC(O)(C(O)=O)C[C@@H](O)C1O AAWZDTNXLSGCEK-LNVDRNJUSA-N 0.000 description 1
- KMVWNDHKTPHDMT-UHFFFAOYSA-N 2,4,6-tripyridin-2-yl-1,3,5-triazine Chemical compound N1=CC=CC=C1C1=NC(C=2N=CC=CC=2)=NC(C=2N=CC=CC=2)=N1 KMVWNDHKTPHDMT-UHFFFAOYSA-N 0.000 description 1
- RTAPDZBZLSXHQQ-UHFFFAOYSA-N 8-methyl-3,7-dihydropurine-2,6-dione Chemical class N1C(=O)NC(=O)C2=C1N=C(C)N2 RTAPDZBZLSXHQQ-UHFFFAOYSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 241000235349 Ascomycota Species 0.000 description 1
- 244000223760 Cinnamomum zeylanicum Species 0.000 description 1
- AAWZDTNXLSGCEK-UHFFFAOYSA-N Cordycepinsaeure Natural products OC1CC(O)(C(O)=O)CC(O)C1O AAWZDTNXLSGCEK-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- CWYNVVGOOAEACU-UHFFFAOYSA-N Fe2+ Chemical compound [Fe+2] CWYNVVGOOAEACU-UHFFFAOYSA-N 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- 241001291893 Monascus argentinensis Species 0.000 description 1
- 241000290967 Monascus aurantiacus Species 0.000 description 1
- 241000059962 Monascus eremophilus Species 0.000 description 1
- 241000059970 Monascus floridanus Species 0.000 description 1
- 241001052469 Monascus kaoliang Species 0.000 description 1
- 241000030999 Monascus pilosus Species 0.000 description 1
- 241000031003 Monascus ruber Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010029216 Nervousness Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- AAWZDTNXLSGCEK-ZHQZDSKASA-N Quinic acid Natural products O[C@H]1CC(O)(C(O)=O)C[C@H](O)C1O AAWZDTNXLSGCEK-ZHQZDSKASA-N 0.000 description 1
- 241000006328 Rhizopus azygosporus Species 0.000 description 1
- 241000303962 Rhizopus delemar Species 0.000 description 1
- 241000593344 Rhizopus microsporus Species 0.000 description 1
- 241000235545 Rhizopus niveus Species 0.000 description 1
- 241000006333 Rhizopus schipperae Species 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 229930003537 Vitamin B3 Natural products 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- -1 alkaloid compounds Chemical class 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000002269 analeptic agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 235000019568 aromas Nutrition 0.000 description 1
- 235000019606 astringent taste Nutrition 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 235000017803 cinnamon Nutrition 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 150000002016 disaccharides Chemical group 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000010200 folin Substances 0.000 description 1
- 238000004362 fungal culture Methods 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 229940074391 gallic acid Drugs 0.000 description 1
- 235000004515 gallic acid Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 229920005610 lignin Polymers 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- DFPAKSUCGFBDDF-UHFFFAOYSA-N nicotinic acid amide Natural products NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229960003975 potassium Drugs 0.000 description 1
- 235000007686 potassium Nutrition 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 235000019640 taste Nutrition 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 235000019160 vitamin B3 Nutrition 0.000 description 1
- 239000011708 vitamin B3 Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23F—COFFEE; TEA; THEIR SUBSTITUTES; MANUFACTURE, PREPARATION, OR INFUSION THEREOF
- A23F5/00—Coffee; Coffee substitutes; Preparations thereof
- A23F5/02—Treating green coffee; Preparations produced thereby
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23F—COFFEE; TEA; THEIR SUBSTITUTES; MANUFACTURE, PREPARATION, OR INFUSION THEREOF
- A23F5/00—Coffee; Coffee substitutes; Preparations thereof
- A23F5/24—Extraction of coffee; Coffee extracts; Making instant coffee
- A23F5/26—Extraction of water-soluble constituents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23F—COFFEE; TEA; THEIR SUBSTITUTES; MANUFACTURE, PREPARATION, OR INFUSION THEREOF
- A23F2200/00—Special features
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/645—Fungi ; Processes using fungi
- C12R2001/845—Rhizopus
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Tea And Coffee (AREA)
Abstract
본 발명은 생리활성물질의 함량이 증진된 발효 커피원두 제조방법 및 상기 방법으로 제조된 발효 커피원두에 관한 것이다. 구체적으로, 본 발명에 따른 제조방법으로 제조된 발효 커피원두는 총 페놀 및 플라보노이드의 함량뿐 아니라, 하이드록시시트르산이나 커피 성분인 트리고넬린, 카페인, 클로로겐산 및 카페인산의 함량이 유의적으로 증가하고, 항산화 활성 및 α-글루코시다제 억제 활성이 증진됨으로써, 기능성 소재로서 유용하게 사용될 수 있다.The present invention relates to a method for producing fermented coffee beans with increased content of bioactive substances and to fermented coffee beans produced by the method. Specifically, fermented coffee beans produced by the production method according to the present invention significantly increase the content of total phenol and flavonoid, as well as the content of hydroxycitric acid or coffee components trigonelline, caffeine, chlorogenic acid, and caffeic acid, As antioxidant activity and α-glucosidase inhibitory activity are enhanced, it can be usefully used as a functional material.
Description
본 발명은 생리활성물질의 함량이 증진된 발효 커피원두 제조방법 및 상기 방법으로 제조된 발효 커피원두에 관한 것이다.The present invention relates to a method for producing fermented coffee beans with increased content of bioactive substances and to fermented coffee beans produced by the method.
커피나무는 꼭두서니과(Rubiaceae) 코페아속(Coffee)에 속하며, 상업적으로 재배하는 품종은 크게 아라비카(Arabica), 로부스타(Robusta) 및 리베리카(Liberica)의 3가지 품종으로 나뉜다. 이러한 커피나무로부터 채취된 커피원두로 제조되는 커피는 쓴맛, 신맛, 단맛, 떫은 맛 등이 다양하게 조화되어 만들어지는 기호음료로서 9세기경부터 에티오피아에서 재배되기 시작한 이래로 2018년에 유럽에서 264만톤, 미국에서 157만톤, 한국에서 15만톤이 소비되어 석유 다음으로 교역량이 많은, 고부가가치의 상품이다.Coffee trees belong to the Coffee genus of the Rubiaceae family, and commercially grown varieties are largely divided into three varieties: Arabica, Robusta, and Liberica. Coffee, which is made from coffee beans collected from these coffee trees, is a favorite beverage made with a variety of flavors such as bitterness, sourness, sweetness, and astringency. Since it began being cultivated in Ethiopia around the 9th century, in 2018, 2.64 million tons were produced in Europe; With 1.57 million tons consumed in the United States and 150,000 tons consumed in Korea, it is a high-value-added product with the second largest volume of trade after oil.
커피는 알츠하이머병, 파킨슨병, 제2형 당뇨병, 콜레스테롤, 심장 질환 및 간경변 등의 치료나 개선에 유의적인 활성을 나타내는 물질이 있음이 보고되면서 기호식품을 넘어서 약리학적 연구도 지속되고 있는 추세이다. 그러나, 커피의 과다섭취는 정서불안, 신경과민, 수면장애 및 위장장애 등을 유발할 수 있다고 알려져 있다.As it has been reported that coffee contains substances that are significantly active in the treatment or improvement of Alzheimer's disease, Parkinson's disease, type 2 diabetes, cholesterol, heart disease, and liver cirrhosis, pharmacological research beyond it as a favorite food is continuing. However, it is known that excessive consumption of coffee can cause emotional anxiety, nervousness, sleep disorders, and gastrointestinal disorders.
커피의 대표적인 성분으로는 카페인, 클로로겐산, 나이아신, 칼륨, 트리고넬, 아미노산 등이 있고, 이중에서 주성분으로 알려진 카페인은 알칼로이드계 화합물의 하나로 냄새가 없고 쓴맛을 내며 물에 잘 녹는다.Representative ingredients of coffee include caffeine, chlorogenic acid, niacin, potassium, trigonel, and amino acids. Among these, caffeine, known as the main ingredient, is one of the alkaloid compounds, has no odor, has a bitter taste, and is highly soluble in water.
한편, 발효는 유산균을 이용한 젖산발효, 초산균을 이용한 초산발효 등이 있으며, 주로 식품에서 특유의 향미를 발생시키거나 미생물의 최종생산물에 의해 유익한 효과를 얻기 위해 널리 이용되는 공정이다. 이에, 커피에서도 발효를 통해 독특한 향을 생성하거나 유익한 활성 성분을 증진시키는 연구들이 진행되고 있다. 이와 관련하여, 대한민국 특허공개 제10-2014-0011235호는 발효 커피 및 그의 제조방법에 관한 것으로, 커피의 생두 또는 내과피의 생두를 발효시킨 생두로 제조된 발효커피가 맛과 향미의 개선으로 품질이 우수한 커피의 생산에 활용될 수 있음을 개시하고 있다.Meanwhile, fermentation includes lactic acid fermentation using lactic acid bacteria and acetic acid fermentation using acetic acid bacteria, and is a widely used process mainly to generate unique flavors in foods or to obtain beneficial effects through the end products of microorganisms. Accordingly, research is being conducted to create unique aromas or enhance beneficial active ingredients in coffee through fermentation. In this regard, Republic of Korea Patent Publication No. 10-2014-0011235 relates to fermented coffee and its manufacturing method. Fermented coffee made from green coffee beans or green coffee beans fermented from endocarp has improved quality due to improved taste and flavor. It is disclosed that it can be used in the production of excellent coffee.
본 발명의 목적은 생리활성물질의 함량이 증진된 발효 커피 제조방법 및 상기 방법으로 제조된 발효 커피를 제공하는 것이다.The purpose of the present invention is to provide a method for producing fermented coffee with increased content of bioactive substances and fermented coffee produced by the method.
상기 목적을 달성하기 위하여, 본 발명은 커피원두에 진균을 접종하고 발효시키는 단계를 포함하는 생리활성물질의 함량이 증진된 발효 커피원두 제조방법을 제공한다.In order to achieve the above object, the present invention provides a method for producing fermented coffee beans with increased content of bioactive substances, which includes the step of inoculating coffee beans with fungi and fermenting them.
또한, 본 발명은 상기 제조방법으로 제조된 생리활성물질의 함량이 증진된 발효 커피원두를 제공한다.In addition, the present invention provides fermented coffee beans with an increased content of bioactive substances prepared by the above production method.
나아가, 본 발명은 커피원두에 진균을 접종하고 발효시키는 단계를 포함하는 커피원두 내 생리활성물질의 함량 증진방법을 제공한다.Furthermore, the present invention provides a method for increasing the content of bioactive substances in coffee beans, including the step of inoculating coffee beans with fungi and fermenting them.
본 발명에 따른 제조방법으로 제조된 발효 커피원두는 총 페놀 및 플라보노이드의 함량 뿐 아니라, 하이드록시시트르산이나 커피 성분인 트리고넬린, 카페인, 클로로겐산 및 카페인산의 함량이 유의적으로 증가하고, 항산화 활성 및 α-글루코시다제 억제 활성이 증진됨으로써, 기능성 소재로서 유용하게 사용될 수 있다.Fermented coffee beans produced by the production method according to the present invention significantly increase the content of total phenol and flavonoid, as well as the content of hydroxycitric acid or coffee components trigonelline, caffeine, chlorogenic acid, and caffeic acid, and have antioxidant activity and As the α-glucosidase inhibitory activity is enhanced, it can be usefully used as a functional material.
이하, 본 발명을 상세히 설명한다.Hereinafter, the present invention will be described in detail.
본 발명은 커피원두에 진균을 접종하고 발효시키는 단계를 포함하는 생리활성물질의 함량이 증진된 발효 커피원두 제조방법을 제공한다.The present invention provides a method for producing fermented coffee beans with increased content of bioactive substances, which includes the step of inoculating coffee beans with fungi and fermenting them.
본 명세서에서 사용된 용어, "커피원두(coffee bean)"는 꼭두서니과(Rubiaceae) 코페아속(Coffee)에 속하는 식물인 커피나무의 씨앗으로, 이를 볶고 뜨거운 물을 사용하여 추출된 것이 커피이다. 커피나무는 심어지고 2년 후에 개화하고, 약 3년후에 빨간색 또는 노란색의 열매를 맺는데, 맺어진 열매에서 외피, 과육, 내과피, 은피를 벗겨낸 씨앗이 커피원두이다. 상기 커피원두는 통상의 기술분야에 알려진 모든 품종의 원두를 포함할 수 있다. 예를 들어, 상기 커피원두는 아라비카(arabica), 로부스타(robusta) 등을 포함할 수 있다. 또한, 상기 커피원두는 가공되기 전이나 가공된 후의 것을 모두 포함할 수 있고, 구체적으로, 상기 가공은 로스팅(roasting)일 수 있다.As used herein, the term "coffee bean" refers to the seeds of the coffee tree, a plant belonging to the genus Coffee of the Rubiaceae family. Coffee is obtained by roasting the seeds and extracting them using hot water. Coffee trees bloom two years after being planted, and bear red or yellow fruit about three years later. Coffee beans are the seeds from which the outer skin, pulp, endocarp, and silver skin have been removed from the fruit. The coffee beans may include all types of coffee beans known in the art. For example, the coffee beans may include Arabica, Robusta, etc. Additionally, the coffee beans may include both before and after processing, and specifically, the processing may be roasting.
상기 진균은 통상의 기술분야에 알려진 모든 종류의 진균을 포함할 수 있고, 구체적으로, 상기 진균은 본체가 실처럼 길고 가는 모양의 균사로 되어 있는 사상균을 의미하며, 조균류, 자낭균류, 불완전균류 등이 포함될 수 있다. 구체적으로, 상기 곰팡이균은 아스퍼질러스 속, 리조푸스 속 및 모나스쿠스 속으로 구성된 군으로부터 선택되는 어느 하나 이상일 수 있다.The fungus may include all types of fungi known in the art. Specifically, the fungus refers to a filamentous fungus whose main body is made of long, thin hyphae like threads, and includes protomycetes, ascomycetes, and imperfect fungi. etc. may be included. Specifically, the fungus may be any one or more selected from the group consisting of Aspergillus genus, Rhizopus genus, and Monascus genus.
상기 진균은 통상의 기술자에 의해 적절한 양으로 접종될 수 있다. 구체적으로, 상기 진균 배양액 1 ㎖ 당 1.0×103 내지 1.0×1010 포자수, 1.0×104 내지 1.0×1010 포자수, 1.0×105 내지 1.0×1010 포자수, 1.0×106 내지 1.0×1010 포자수, 1.0×103 내지 1.0×109 포자수, 1.0×104 내지 1.0×109 포자수, 1.0×105 내지 1.0×109 포자수, 1.0×106 내지 1.0×109 포자수, 1.0×103 내지 1.0×108 포자수, 1.0×104 내지 1.0×108 포자수, 1.0×105 내지 1.0×108 포자수 또는 1.0×106 내지 1.0×108 포자수로 접종될 수 있다.The fungus can be inoculated in an appropriate amount by a person skilled in the art. Specifically, the number of spores per 1 ml of the fungal culture medium is 1.0×10 3 to 1.0×10 10 , 1.0×10 4 to 1.0×10 10 spores, 1.0×10 5 to 1.0×10 10 spores, 1.0×10 6 to 1.0×10 10 Number of spores, 1.0×10 3 to 1.0×10 9 Number of spores, 1.0×10 4 to 1.0×10 9 Number of spores, 1.0×10 5 to 1.0×10 9 Number of spores, 1.0×10 6 to 1.0×10 9 Number of spores, 1.0×10 It can be inoculated with 3 to 1.0×10 8 spores, 1.0×10 4 to 1.0×10 8 spores, 1.0×10 5 to 1.0×10 8 spores, or 1.0×10 6 to 1.0×10 8 spores.
상기 발효는 통상의 기술분야에 알려진 방법에 따라 수행될 수 있다. 일례로, 상기 발효는 고체발효, 액체발효 또는 이의 혼합일 수 있다. 이때, 발효 온도 및 기간은 통상의 기술자에 의해 적절히 선택되어 수행될 수 있다. 구체적으로, 발효는 23 내지 40℃, 23 내지 37℃, 23 내지 33℃, 25 내지 40℃, 25 내지 37℃, 25 내지 33℃, 28 내지 40℃, 28 내지 37℃ 또는 28 내지 33℃의 온도로 1 내지 25일, 1 내지 20일, 1 내지 15일, 1 내지 10일, 1 내지 7일, 3 내지 25일, 3 내지 20일, 3 내지 15일, 3 내지 10일 또는 3 내지 7일 동안 수행될 수 있다.The fermentation can be performed according to methods known in the art. For example, the fermentation may be solid fermentation, liquid fermentation, or a combination thereof. At this time, the fermentation temperature and period can be appropriately selected and performed by a person skilled in the art. Specifically, fermentation is carried out at 23 to 40°C, 23 to 37°C, 23 to 33°C, 25 to 40°C, 25 to 37°C, 25 to 33°C, 28 to 40°C, 28 to 37°C, or 28 to 33°C. 1 to 25 days, 1 to 20 days, 1 to 15 days, 1 to 10 days, 1 to 7 days, 3 to 25 days, 3 to 20 days, 3 to 15 days, 3 to 10 days or 3 to 7 days. It can be done in one day.
한편, 상기 리조푸스 속 균주는 리조푸스 올리고스포러스(Rhizopus oligosporus), 리조푸스 델레마(Rhizopus delemar), 리조푸스 자포니쿠스(Rhizopus japonicus), 리조푸스 오리재(Rhizopus oryzae), 리조푸스 아리주스(Rhizopus arrhizus), 리조푸스 니베우스(Rhizopus niveus), 리조푸스 아지고스포루스(Rhizopus azygosporus), 리조푸스 미크로스포루스(Rhizopus microsporus), 리조푸스 쉬페라에(Rhizopus schipperae) 및 리조푸스 스톨로니퍼(Rhizopus stolonifer)로 구성된 군으로부터 선택되는 어느 하나 이상의 균주일 수 있다. 본 발명의 일 실시예에서, 상기 리조푸스 속 균주는 리조푸스 올리고스포러스 균주일 수 있고, 더욱 구체적으로는 기탁번호 KCCM11948P로 수탁된 리조푸스 올리고스포러스 균주일 수 있다.On the other hand, the Rhizopus genus strains include Rhizopus oligosporus , Rhizopus delemar , Rhizopus japonicus, Rhizopus oryzae , and Rhizopus arijus. ( Rhizopus arrhizus ), Rhizopus niveus , Rhizopus azygosporus, Rhizopus microsporus , Rhizopus schipperae and Rhizopus stolonifer. It may be any one or more strains selected from the group consisting of ( Rhizopus stolonifer ). In one embodiment of the present invention, the Rhizopus genus strain may be a Rhizopus oligosporus strain, and more specifically, it may be a Rhizopus oligosporus strain deposited under the accession number KCCM11948P.
또한, 상기 모나스쿠스 속 균주는 모나스쿠스 카오리앙(Monascus kaoliang), 모나스쿠스 필로수스(Monascus pilosus), 모나스쿠스 아우란티아쿠스(Monascus aurantiacus), 모나스쿠스 플로리다누스(Monascus floridanus), 모나스쿠스 에레모필루스(Monascus eremophilus), 모나스쿠스 루버(Monascus ruber), 모나스쿠스 퍼푸레우스(Monascus purpureus) 및 모나스쿠스 아르젠티넨시스(Monascus argentinensis)로 구성된 군으로부터 선택되는 어느 하나 이상의 균주일 수 있다. 본 발명의 일 실시예에서, 상기 모나스쿠스 속 균주는 모나스쿠스 퍼푸레우스 균주일 수 있고, 더욱 구체적으로는 기탁번호 KCCM13045P로 수탁된 모나스쿠스 퍼푸레우스 균주일 수 있다.In addition, the Monascus genus strains include Monascus kaoliang , Monascus pilosus, Monascus aurantiacus , Monascus floridanus , and Monascus eremophil. It may be any one or more strains selected from the group consisting of Monascus eremophilus , Monascus ruber , Monascus purpureus , and Monascus argentinensis . In one embodiment of the present invention, the Monascus genus strain may be a Monascus purpureus strain, and more specifically, it may be a Monascus purpureus strain deposited under the accession number KCCM13045P.
본 발명에 따른 방법은 커피원두 내 생리활성물질의 함량을 증진시킬 수 있다. 상기 생리활성물질은 생체의 기능을 증진시키거나 억제시켜 생체 내에서 기능조절에 관여하는 물질을 의미한다. 상기 생리활성물질은 통상의 기술분야에 알려진 모든 물질을 포함할 수 있고, 구체적으로 상기 생리활성물질은 커피원두 내 존재한다고 알려진 물질뿐 아니라, 진균 접종으로 인한 발효과정에 의해 새롭게 생성될 수 있는 물질도 모두 포함할 수 있다. 일례로, 상기 생리활성물질은 하이드록시시트르산, 트리고넬린, 카페인, 클로로겐산 및 카페인산으로 구성된 군으로부터 선택되는 어느 하나 이상일 수 있다.The method according to the present invention can increase the content of bioactive substances in coffee beans. The bioactive substance refers to a substance that participates in regulating functions in the living body by enhancing or inhibiting the functions of the living body. The bioactive substances may include all substances known in the art. Specifically, the bioactive substances include not only substances known to exist in coffee beans, but also substances that can be newly created through a fermentation process due to fungal inoculation. All may also be included. For example, the bioactive substance may be any one or more selected from the group consisting of hydroxycitric acid, trigonelline, caffeine, chlorogenic acid, and caffeic acid.
또한, 본 발명에 따른 방법으로 제조된 커피원두는 생리활성물질이 증진됨에 따라 증진된 생리활성물질에 의해 나타나는 효과 또한 증진될 수 있다. 일례로, 상기 하이드록시시트르산은 시트르산(citric acid)에서 유래된 물질로, 당에서 지방을 합성하는 경로에 관여하는 ACL(ATP-citrate lyases) 효소가 구연산으로부터 아세틸-CoA(acetyl-CoA)를 합성할 때, 경쟁적으로 상기 효소에 결합하여 아세틸-CoA의 합성을 저해함으로써, 지방의 합성을 억제하는 것으로 알려져 있다. 또한, 상기 트리고넬린은 알칼로이드 계열로 비타민 B3의 합성에 관여하고, 암의 발생 억제, 항당뇨 활성, 충치 유발 균의 억제 등과 같은 활성이 공지되어 있다. 또한, 상기 카페인은 메틸크산틴 계열의 중추신경계 각성제로서, 수용체에 대한 아데노신 작용을 가역적으로 차단하여 아데노신에 의한 졸음을 예방할 뿐 아니라 집중력 상승, 체지방 감소 등의 활성을 나타내는 것으로 알려져 있다. 또한, 클로로겐산은 카페인산과 퀸산의 에스테르 결합으로 구성된 화합물로 리그닌 생합성에서 중요한 중간체 역할을 하며, 식후 혈중 포도당의 방출을 지연시켜 항당뇨 활성을 나타내는 것으로 알려져 있다. 나아가, 카페인산은 항균, 항바이러스, 항암, 해독, 혈액 응고 등의 활성을 나타내는 것으로 알려져 있다. 즉, 본 발명에 따른 방법으로 제조된 커피원두는 상기 서술한 바와 같은 효과를 달성하기 위한 기능성 소재로서 사용될 수 있다.In addition, as the bioactive substances of coffee beans produced by the method according to the present invention are enhanced, the effects exhibited by the enhanced bioactive substances can also be enhanced. For example, the hydroxycitric acid is a substance derived from citric acid, and the ACL (ATP-citrate lyases) enzyme involved in the pathway for synthesizing fat from sugar synthesizes acetyl-CoA from citric acid. It is known to inhibit fat synthesis by competitively binding to the enzyme and inhibiting the synthesis of acetyl-CoA. In addition, trigonelline is an alkaloid that is involved in the synthesis of vitamin B3 and is known to have activities such as inhibiting the development of cancer, anti-diabetic activity, and inhibiting cavity-causing bacteria. In addition, caffeine is a central nervous system stimulant of the methylxanthine series, and is known to not only prevent drowsiness caused by adenosine by reversibly blocking the action of adenosine on receptors, but also to increase concentration and reduce body fat. In addition, chlorogenic acid is a compound composed of an ester bond of caffeic acid and quinic acid, which serves as an important intermediate in lignin biosynthesis, and is known to exhibit anti-diabetic activity by delaying the release of glucose into the blood after a meal. Furthermore, caffeic acid is known to exhibit antibacterial, antiviral, anticancer, detoxification, and blood coagulation activities. In other words, coffee beans produced by the method according to the present invention can be used as a functional material to achieve the effects described above.
본 발명은 상기 제조방법으로 제조된 생리활성물질의 함량이 증진된 발효 커피원두를 제공한다.The present invention provides fermented coffee beans with increased content of bioactive substances prepared by the above production method.
본 발명에 따른 발효 커피원두는 상기 서술한 바와 같은 특징을 갖는 제조방법으로 제조될 수 있다. 일례로, 상기 발효 커피원두는 진균을 접종하고 발효시켜 제조될 수 있다. 한편, 상기 생리활성물질은 하이드록시시트르산, 트리고넬린, 카페인, 클로로겐산 및 카페인산으로 구성된 군으로부터 선택되는 어느 하나 이상일 수 있다. 즉, 상기 발효 커피원두는 생리활성물질에 의해 나타나는 효과를 달성하기 위한 기능성 소재로서 사용될 수 있다.Fermented coffee beans according to the present invention can be produced by a production method having the characteristics described above. For example, the fermented coffee beans can be produced by inoculating fungi and fermenting them. Meanwhile, the bioactive substance may be any one or more selected from the group consisting of hydroxycitric acid, trigonelline, caffeine, chlorogenic acid, and caffeic acid. In other words, the fermented coffee beans can be used as a functional material to achieve the effects produced by bioactive substances.
나아가, 본 발명은 커피원두에 진균을 접종하고 발효시키는 단계를 포함하는 커피원두 내 생리활성물질의 함량 증진방법을 제공한다.Furthermore, the present invention provides a method for increasing the content of bioactive substances in coffee beans, including the step of inoculating coffee beans with fungi and fermenting them.
본 발명에 다른 커피원두 내 생리활성물질의 함량 증진방법은 상기 서술한 바와 같은 특징을 가질 수 있다. 일례로, 상기 증진방법은 진균을 접종하고 발효시켜 제조될 수 있다. 한편, 상기 생리활성물질은 하이드록시시트르산, 트리고넬린, 카페인, 클로로겐산 및 카페인산으로 구성된 군으로부터 선택되는 어느 하나 이상일 수 있다.The method for increasing the content of bioactive substances in coffee beans according to the present invention may have the characteristics described above. For example, the enhancement method can be prepared by inoculating and fermenting fungi. Meanwhile, the bioactive substance may be any one or more selected from the group consisting of hydroxycitric acid, trigonelline, caffeine, chlorogenic acid, and caffeic acid.
이하, 본 발명을 하기 실시예에 의해 상세히 설명한다. 단, 하기 실시예는 본 발명을 예시하기 위한 것일 뿐, 이들에 의해 본 발명이 제한되는 것은 아니다. 본 발명의 청구범위에 기재된 기술적 사상과 실질적으로 동일한 구성을 갖고 동일한 작용 효과를 이루는 것은 어떠한 것이라도 본 발명의 기술적 범위에 포함된다.Hereinafter, the present invention will be explained in detail by the following examples. However, the following examples are only for illustrating the present invention, and the present invention is not limited thereto. Anything that has substantially the same structure as the technical idea described in the claims of the present invention and achieves the same operation and effect is included in the technical scope of the present invention.
실시예 1. 발효 커피원두의 제조-(1)Example 1. Production of fermented coffee beans-(1)
진균을 이용하여 다음과 같은 방법으로 발효 커피원두를 제조하였다.Fermented coffee beans were prepared using fungi in the following manner.
먼저, 1 ㎏의 생두를 6시간 동안 물에 침지시킨 후, 121℃에서 15분 동안 멸균시켰다. 멸균된 생두에 모나스커스 퍼푸레우스(Monascus purpureus, KCCM13045P) 균주를 2×107개의 포자(spore)가 되도록 접종하여 5일 동안 발효시켰다. 발효가 끝난 후, 생두를 세척하고 60℃에서 2시간 동안 건조시켜 수분함량이 10 내지 11%가 되도록 조절하였다. 이후, 생두를 240℃에서 17분 동안 중배전으로 로스팅하여 사용전까지 보관하였다.First, 1 kg of green coffee beans were immersed in water for 6 hours and then sterilized at 121°C for 15 minutes. Monascus purpureus (KCCM13045P) strain was inoculated into sterilized green coffee beans to produce 2×10 7 spores and fermented for 5 days. After fermentation was completed, the green beans were washed and dried at 60°C for 2 hours to adjust the moisture content to 10 to 11%. Afterwards, the green coffee beans were roasted at medium roast for 17 minutes at 240°C and stored until use.
실시예 2. 발효 커피원두의 제조-(2)Example 2. Production of fermented coffee beans-(2)
모나스커스 퍼푸레우스 균주를 접종하여 발효시킬 때, 40 g의 계피 농축액(65 브릭스)을 첨가한 것을 제외하고는, 상기 실시예 1과 동일한 조건 및 방법으로 발효 커피원두를 제조하였다.Fermented coffee beans were prepared under the same conditions and methods as in Example 1, except that 40 g of cinnamon concentrate (65 brix) was added when inoculating and fermenting the Monascus purpureus strain.
실시예 3. 발효 커피원두의 제조-(3)Example 3. Production of fermented coffee beans-(3)
모나스커스 퍼푸레우스 균주 대신 리조푸스 올리고스포러스(Rhizopus oligosporus, KCCM11948P) 균주를 사용한 것을 제외하고는, 상기 실시예 1과 동일한 조건 및 방법으로 발효 커피원두를 제조하였다.Fermented coffee beans were prepared under the same conditions and methods as in Example 1, except that Rhizopus oligosporus (KCCM11948P) strain was used instead of Monascus purpureus strain.
실시예 4. 발효 커피의 제조-(4)Example 4. Preparation of fermented coffee-(4)
모나스커스 퍼푸레우스 균주 대신 리조푸스 올리고스포러스 균주를 사용한 것을 제외하고는, 상기 실시예 2와 동일한 조건 및 방법으로 발효 커피원두를 제조하였다.Fermented coffee beans were prepared under the same conditions and methods as in Example 2, except that Rhizopus oligosporus strain was used instead of Monascus purpureus strain.
비교예 1. 발효되지 않은 커피원두의 제조Comparative Example 1. Preparation of unfermented coffee beans
상기 서술한 바와 같이 생두를 멸균하고, 60℃에서 2시간 동안 건조시켜 수분함량이 10 내지 11%가 되도록 조절하였다. 이후, 생두를 240℃에서 17분 동안 중배전으로 로스팅하여 발효되지 않은 커피원두를 제조하였다.As described above, green coffee beans were sterilized and dried at 60°C for 2 hours to adjust the moisture content to 10 to 11%. Afterwards, unfermented coffee beans were prepared by roasting the green beans at medium roasting for 17 minutes at 240°C.
실험예 1. 하이드록시시트르산(hydroxycitric acid, HCA) 함량 확인Experimental Example 1. Confirmation of hydroxycitric acid (HCA) content
발효된 커피원두에 존재하는 하이드록시시트르산 함량을 HPLC 분석방법으로 다음과 같이 확인하였다.The hydroxycitric acid content present in fermented coffee beans was confirmed using HPLC analysis as follows.
먼저, 상기에서 제조된 10 g의 발효 커피원두를 100 ㎖의 물에 넣어 커피를 추출하고, 수득된 추출물을 동결건조하여 분말을 얻었다. 상기 분말 30 ㎎을 1 M의 HCl에 현탁시키고, 15,000 ×g의 조건으로 10분 동안 원심분리하여 상층액을 수득하였다. 수득된 상층액을 0.2 ㎛ 크기의 포어(pore)를 갖는 GHP 막 실린지 필터(GHP membrane syringe filter, Pall, 미국)로 여과한 후, 20 ㎕를 HPLC 컬럼에 주입하였다. 이때, HPLC 조건을 하기 표 1에, HCA 정량분석 결과를 표 2에 나타내었다.First, 10 g of fermented coffee beans prepared above were placed in 100 ml of water to extract coffee, and the obtained extract was freeze-dried to obtain powder. 30 mg of the powder was suspended in 1 M HCl and centrifuged at 15,000 × g for 10 minutes to obtain a supernatant. The obtained supernatant was filtered through a GHP membrane syringe filter (Pall, USA) with pores of 0.2 μm in size, and then 20 μl was injected into the HPLC column. At this time, the HPLC conditions are shown in Table 1 below, and the HCA quantitative analysis results are shown in Table 2.
표 2에 나타난 바와 같이, 발효되지 않은 커피원두와 비교하여 발효 커피원두에서 HCA의 함량이 유의적으로 현저히 증가하였다.As shown in Table 2, the content of HCA significantly increased in fermented coffee beans compared to unfermented coffee beans.
실험예 2. 커피성분 분석Experimental Example 2. Coffee component analysis
발효된 커피원두에 존재하는 커피성분인 트리고넬린(trigonelline), 카페인(caffeine), 클로로겐산(chlorogenic acid) 및 카페인산(caffeeic acid)의 함량을 HPLC 분석방법으로 다음과 같이 확인하였다.The contents of trigonelline, caffeine, chlorogenic acid, and caffeeic acid, which are coffee components present in fermented coffee beans, were confirmed using HPLC analysis as follows.
먼저, 상기 실험예 1에 기재된 바와 같이 커피원두로부터 시료를 수득하고, 하기 표 3 및 4에 기재된 조건에 따라 HPLC를 수행하였다. 그 결과, 커피 성분의 정량분석 결과를 도 5에 나타내었다.First, samples were obtained from coffee beans as described in Experimental Example 1, and HPLC was performed according to the conditions shown in Tables 3 and 4 below. As a result, the results of quantitative analysis of coffee components are shown in Figure 5.
B: 100% 아세토니트릴A: Distilled phosphoric acid (50 mM phosphoric acid)
B: 100% acetonitrile
(㎎/g 커피)trigonelline
(mg/g coffee)
(㎎/g 커피)Caffeine
(mg/g coffee)
(㎎/g 커피)chlorogenic acid
(mg/g coffee)
(㎍/g 커피)caffeic acid
(㎍/g coffee)
표 5에 나타난 바와 같이, 발효되지 않은 커피원두와 비교하여 발효 커피원두에서 커피 성분인 트리고넬린, 카페인, 클로로겐산 및 카페인산의 함량이 유의적으로 현저히 증가하였다.As shown in Table 5, the content of coffee components trigonelline, caffeine, chlorogenic acid, and caffeic acid significantly increased in fermented coffee beans compared to unfermented coffee beans.
실험예 3. 총 페놀 및 플라보노이드 함량Experimental Example 3. Total phenol and flavonoid content
발효된 커피원두에 존재하는 총 페놀 및 플라보노이드 함량을 다음과 같이 확인하였다.The total phenol and flavonoid contents present in fermented coffee beans were confirmed as follows.
먼저 총 페놀 함량 측정을 위해, 1 ㎎의 동결건조된 커피원두를 1 ㎖의 물에 희석하고, 15,000×g의 조건으로 10분 동안 원심분리하여 상층액을 회수하였다. 상기 회수된 상층액 150 ㎍을 96웰 플레이트에 넣고, 15 ㎍의 폴린 시약(folin reagent) 및 10% Na2CO3을 첨가하였다. 이를 28℃ 및 암조건에서 30분 동안 반응시킨 후, 분광광도계(Molecular Device, Syunnyvale, 미국)를 사용하여 765 ㎚의 파장에서 흡광도를 측정하였다. 이때, 표준물질로 갈산(GAE)을 사용하여 표준그래프를 작성하고, 이로부터 총 페놀 함량을 계산하였다.First, to measure the total phenol content, 1 mg of freeze-dried coffee beans was diluted in 1 ml of water, centrifuged at 15,000 × g for 10 minutes, and the supernatant was recovered. 150 μg of the recovered supernatant was placed in a 96-well plate, and 15 μg of folin reagent and 10% Na 2 CO 3 were added. After reacting for 30 minutes at 28°C and dark conditions, the absorbance was measured at a wavelength of 765 nm using a spectrophotometer (Molecular Device, Syunnyvale, USA). At this time, a standard graph was prepared using gallic acid (GAE) as a standard material, and the total phenol content was calculated from this.
한편, 총 플라보노이드 함량 측정을 위해, 2 ㎎의 동결건조된 커피원두를 1 ㎖의 메탄올에 희석하고, 15,000×g의 조건으로 10분 동안 원심분리하여 상층액을 회수하였다. 상기 회수된 상층액 20 ㎍을 96웰 플레이트에 넣고, 60 ㎍의 에탄올, 10 ㎍의 10% AlCl3, 10 ㎍의 1M CH3COOK 및 100 ㎍의 물을 첨가하였다. 이를 28℃ 및 암조건에서 30분 동안 반응시킨 후, 분광광도계를 사용하여 415 ㎚의 파장에서 흡광도를 측정하였다. 이때, 표준물질로 퀘르세틴(QE)을 사용하여 표준그래프를 작성하고, 이로부터 총 페놀 함량을 계산하였다. 그 결과, 계산된 총 페놀 및 플라보노이드의 함량을 표 6에 나타내었다.Meanwhile, to measure the total flavonoid content, 2 mg of freeze-dried coffee beans were diluted in 1 ml of methanol, centrifuged at 15,000 × g for 10 minutes, and the supernatant was recovered. 20 μg of the recovered supernatant was placed in a 96-well plate, and 60 μg of ethanol, 10 μg of 10% AlCl 3 , 10 μg of 1M CH 3 COOK, and 100 μg of water were added. After reacting for 30 minutes at 28°C and dark conditions, the absorbance was measured at a wavelength of 415 nm using a spectrophotometer. At this time, a standard graph was prepared using quercetin (QE) as a standard material, and the total phenol content was calculated from this. As a result, the calculated total phenol and flavonoid contents are shown in Table 6.
(㎎ GAE/g 커피)Total phenol content
(mg GAE/g coffee)
(㎎ QE/g 커피)Total flavonoid content
(mg QE/g coffee)
표 6에 나타난 바와 같이, 발효되지 않은 커피원두와 비교하여 발효 커피원두에서 총 페놀 및 플라보노이드의 함량이 유의적으로 현저히 증가하였다.As shown in Table 6, the content of total phenols and flavonoids significantly increased in fermented coffee beans compared to unfermented coffee beans.
실험예 4. 항산화 활성Experimental Example 4. Antioxidant activity
발효된 커피원두의 항산화 활성을 다음과 같이 확인하였다.The antioxidant activity of fermented coffee beans was confirmed as follows.
4-1. DPPH 라디칼 소거능4-1. DPPH radical scavenging ability
1 ㎎의 동결건조된 커피원두를 1 ㎖의 메탄올에 희석하고, 15,000×g의 조건으로 10분 동안 원심분리하여 상층액을 회수하였다. 상기 회수된 상층액 40 ㎍을 96웰 플레이트에 넣고, 40 ㎍의 에탄올 및 20 ㎍의 DPPH를 첨가하였다. 이를 30℃ 및 암조건에서 30분 동안 반응시킨 후, 분광광도계를 사용하여 517 ㎚의 파장에서 흡광도를 측정하였다. 측정된 흡광도 값으로부터 라디칼 형성을 50% 억제하는데 필요한 시료의 농도(SC50)을 계산하였다.1 mg of freeze-dried coffee beans was diluted in 1 ml of methanol, centrifuged at 15,000 × g for 10 minutes, and the supernatant was recovered. 40 μg of the recovered supernatant was placed in a 96-well plate, and 40 μg of ethanol and 20 μg of DPPH were added. After reacting for 30 minutes at 30°C and dark conditions, the absorbance was measured at a wavelength of 517 nm using a spectrophotometer. The sample concentration (SC 50 ) required to inhibit radical formation by 50% was calculated from the measured absorbance value.
4-2. FRAP 분석4-2. FRAP analysis
1 ㎎의 동결건조된 커피원두를 1 ㎖의 물에 희석하고, 15,000×g의 조건으로 10분 동안 원심분리하여 상층액을 회수하였다. 상기 회수된 상층액 6 ㎍을 96웰 플레이트에 넣고, 18 ㎍의 물, 180 ㎍의 반응 용액(0.3 M CH3COONa 완충액(pH 3.6), 0.01M TPTZ를 포함하는 0.04 M HCl 용액 및 0.02 M FeCl3·6H2O를 10:1:1의 부피비로 혼합한 혼합액)을 첨가하였다. 이를 37℃ 및 암조건에서 30분 동안 반응시킨 후, 분광광도계를 사용하여 593 ㎚의 파장에서 흡광도를 측정하였다. 이때, 표준물질로 FeSO4·7H2를 사용하여 표준그래프를 작성하고, 이로부터 환원된 철의 농도를 계산하였다. 그 결과, DPPH 라디칼 소거능 및 FRAP 분석을 통한 발효 커피원두의 항산화 활성을 확인한 결과를 표 7에 나타내었다.1 mg of freeze-dried coffee beans was diluted in 1 ml of water, centrifuged at 15,000 × g for 10 minutes, and the supernatant was recovered. 6 μg of the recovered supernatant was placed in a 96-well plate, and 18 μg of water, 180 μg of reaction solution (0.3 M CH 3 COONa buffer (pH 3.6), 0.04 M HCl solution containing 0.01 M TPTZ, and 0.02 M FeCl A mixture of 3 ·6H 2 O at a volume ratio of 10:1:1 was added. After reacting for 30 minutes at 37°C and dark conditions, the absorbance was measured at a wavelength of 593 nm using a spectrophotometer. At this time, a standard graph was prepared using FeSO 4 ·7H 2 as a standard material, and the concentration of reduced iron was calculated from this. As a result, the results of confirming the antioxidant activity of fermented coffee beans through DPPH radical scavenging ability and FRAP analysis are shown in Table 7.
(㎍/㎖, SC50)DPPH
(㎍/㎖, SC 50 )
(mM Fe(II)/g 커피)FRAP
(mM Fe(II)/g coffee)
표 7에 나타난 바와 같이, 발효되지 않은 커피원두와 비교하여 발효 커피원두에서 항산화 활성이 유의적으로 현저히 증가하였다.As shown in Table 7, antioxidant activity was significantly increased in fermented coffee beans compared to unfermented coffee beans.
실험예 5. α-글루코시다제 억제 활성Experimental Example 5. α-Glucosidase inhibitory activity
발효된 커피원두의 α-글루코시다제 억제 활성을 다음과 같이 확인하였다.The α-glucosidase inhibitory activity of fermented coffee beans was confirmed as follows.
구체적으로, 1 ㎎의 동결건조된 커피원두를 1 ㎖의 물에 희석하고, 15,000×g의 조건으로 10분 동안 원심분리하여 상층액을 회수하였다. 상기 회수된 상층액 40 ㎕에 40 ㎕의 0.5 M 인산완충액(pH 6.8) 및 0.1 U/㎖의 α-글루코시다제를 첨가하고, 37℃에서 5분 동안 반응시켰다. 여기에 40 ㎕의 5 M pNPG 기질을 첨가하고 8분 동안 반응시킨 후, 300 ㎕의 250 mM Na2CO3를 첨가하여 반응을 종결시키고 스펙트라맥스 M3(SpectraMax M3)를 사용하여 405 ㎚의 파장에서 흡광도를 측정하였다. 측정된 흡광도 값으로부터 α-글루코시다제 억제 활성을 계산한 결과를 표 8에 나타내었다.Specifically, 1 mg of freeze-dried coffee beans was diluted in 1 ml of water, centrifuged at 15,000 × g for 10 minutes, and the supernatant was recovered. To 40 μl of the recovered supernatant, 40 μl of 0.5 M phosphate buffer (pH 6.8) and 0.1 U/ml of α-glucosidase were added and reacted at 37°C for 5 minutes. After adding 40 ㎕ of 5 M pNPG substrate and reacting for 8 minutes, the reaction was terminated by adding 300 ㎕ of 250 mM Na 2 CO 3 and analyzed at a wavelength of 405 ㎚ using SpectraMax M3. Absorbance was measured. The results of calculating the α-glucosidase inhibitory activity from the measured absorbance values are shown in Table 8.
표 8에 나타난 바와 같이, 발효되지 않은 커피원두와 비교하여 발효 커피원두에서 α-글루코시다제 억제 활성이 유의적으로 현저히 증가하였다. α-글루코시다제는 체내에서 이당류가 단당류로 분해되는 것을 억제하여 혈당 상승을 억제하여 항당뇨 활성을 나타내는데, 본 발명에 따른 발효 커피원두는 우수한 α-글루코시다제 억제 활성을 나타냄으로써, 항당뇨 활성을 갖는 기능성 소재로 유용하게 사용될 수 있다.As shown in Table 8, the α-glucosidase inhibitory activity was significantly increased in fermented coffee beans compared to unfermented coffee beans. α-Glucosidase inhibits the decomposition of disaccharides into monosaccharides in the body and suppresses the rise in blood sugar, thereby exhibiting anti-diabetic activity. Fermented coffee beans according to the present invention exhibit excellent α-glucosidase inhibitory activity, thereby suppressing anti-diabetic activity. It can be usefully used as an active functional material.
Claims (9)
A method for producing fermented coffee beans with increased content of bioactive substances, comprising the step of inoculating coffee beans with fungi and fermenting them.
The method of claim 1, wherein the physiologically active substance is at least one selected from the group consisting of hydroxycitric acid, trigonelline, caffeine, chlorogenic acid, and caffeic acid.
The method of producing fermented coffee beans according to claim 1, wherein the fungus is at least one selected from the group consisting of Aspergillus genus, Rhizopus genus, and Monascus genus.
The method of claim 3, wherein the Rhizopus genus is a Rhizopus oligosporus strain.
The method of producing fermented coffee beans according to claim 4, wherein the Rhizopus oligosporus strain is a strain deposited under the accession number KCCM11948P.
The method for producing fermented coffee beans according to claim 3, wherein the Monascus genus is a Monascus purpureus strain.
The method of claim 6, wherein the Monascus purpureus strain is a strain deposited under the accession number KCCM13045P.
Fermented coffee beans with increased content of biologically active substances manufactured by the manufacturing method according to claim 1.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020220100797 | 2022-08-11 | ||
KR20220100797 | 2022-08-11 |
Publications (1)
Publication Number | Publication Date |
---|---|
KR20240023373A true KR20240023373A (en) | 2024-02-21 |
Family
ID=90052784
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020230104699A KR20240023373A (en) | 2022-08-11 | 2023-08-10 | Manufacturing method of fermented coffee bean enhancing of biologically active substance and fermented coffee bean manufactured same |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR20240023373A (en) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20140011235A (en) | 2012-07-17 | 2014-01-28 | 주식회사 엘지생활건강 | Fermented coffee and process for preparing the same |
-
2023
- 2023-08-10 KR KR1020230104699A patent/KR20240023373A/en unknown
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20140011235A (en) | 2012-07-17 | 2014-01-28 | 주식회사 엘지생활건강 | Fermented coffee and process for preparing the same |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR20180036346A (en) | Method for cultivating Camellia sinensis by extreme shading of the light, and the green tea obtained by the method | |
KR20080113175A (en) | The method for making functional drinks using phellinus linteus and product thereof | |
KR102386296B1 (en) | Complex-fermented composition of Fabaton soybean leaves and Schisandra chinensis having enhanced anti-diabetic and anti-obesity effects and preparation method thereof | |
KR101871247B1 (en) | Functional grain syrup containing prunus mume extract and preparing method thereof | |
KR101064139B1 (en) | Preparation method for functional yoghurt using pueraria thunbergiana | |
CN101444242A (en) | Production method of gingko health protection tea | |
KR101457615B1 (en) | A method of manufacturing fermented coffee Phellinus | |
KR101770891B1 (en) | Makgeolli manufacturing method of using roasted coffee ground residue extracts | |
KR101219650B1 (en) | Process for detoxification of Rhus Verniciflua, and the use of detoxified bark extract | |
KR101963978B1 (en) | Composition of fermented sprout ginseng having increased ginsenosides Rh2 and compound K, bioactive components, and preparation method thereof | |
KR102104175B1 (en) | Method for producing functional fermented dutch coffee | |
KR102187229B1 (en) | Preparation of Mixed Tea Composition Comprising Agarwood for Improving Efficacy of Anti-inflammation and Anti-virus | |
KR102298700B1 (en) | Facturing method of functional liquefied healthfoods using Gastroia elata Blume and Polygonum multiflorum Thunberg | |
KR102295062B1 (en) | Method for Manufacturing Beer Containing Coffee | |
KR20240023373A (en) | Manufacturing method of fermented coffee bean enhancing of biologically active substance and fermented coffee bean manufactured same | |
EP3375295B1 (en) | Method for processing green coffee beans | |
EP0478859B1 (en) | Process for improving the qualities of coffee beans | |
KR20200045116A (en) | Composition comprising natural complex extract for protecting liver and relieving hangover | |
KR102253641B1 (en) | Method for producing saponin coffee using material having improvement effects of diet and immunity | |
KR20230129136A (en) | Composition for antibacterial, antioxidant, or anti-inflammatory comprising fermented extracts of Canavalia gladiata leaf as an active ingredient | |
US20230217947A1 (en) | Method for producing fermented green coffee beans by complex fermentation and fermented green coffee beans produced thereby | |
KR101396844B1 (en) | Manufacturing method of alcohol beverage using barley grains | |
KR101685199B1 (en) | Preparation method of red garlic wine | |
CN110063439A (en) | A kind of albumen mulberry drink and preparation method thereof | |
KR102207077B1 (en) | Method for producing fermented coffee comprising a step of wet fermentation and dry fermentation using fresh coffee bean component |